These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 20807189)

  • 41. [Angiogenesis - possibilities, problems and perspectives].
    Kurzyk A
    Postepy Biochem; 2015; 61(1):25-34. PubMed ID: 26281351
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The function of vascular endothelial growth factor.
    Nieves BJ; D'Amore PA; Bryan BA
    Biofactors; 2009; 35(4):332-7. PubMed ID: 19415738
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
    Tandle A; Libutti SK
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibitors of Angiogenesis in Cancer Therapy - Synthesis and Biological Activity.
    Gensicka M; Głowacka A; Dzierzbicka K; Cholewinski G
    Curr Med Chem; 2015; 22(33):3830-47. PubMed ID: 26337104
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis.
    Cao Y; Liu Q
    Adv Cancer Res; 2007; 97():203-24. PubMed ID: 17419947
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vascular endothelial growth factor and its inhibitors.
    Verheul HM; Pinedo HM
    Drugs Today (Barc); 2003; 39 Suppl C():81-93. PubMed ID: 14988747
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors.
    Ishak RS; Aad SA; Kyei A; Farhat FS
    Crit Rev Oncol Hematol; 2014 May; 90(2):152-64. PubMed ID: 24355408
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting.
    Bikfalvi A; Bicknell R
    Trends Pharmacol Sci; 2002 Dec; 23(12):576-82. PubMed ID: 12457776
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
    Ferrara N; Hillan KJ; Novotny W
    Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
    Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
    Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current protein-based anti-angiogenic therapeutics.
    Chakrabarti S; Barrow CJ; Kanwar RK; Ramana V; Kanwar JR
    Mini Rev Med Chem; 2014; 14(3):291-312. PubMed ID: 24552262
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
    Homsi J; Daud AI
    Cancer Control; 2007 Jul; 14(3):285-94. PubMed ID: 17615535
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current insights on the biology and clinical aspects of VEGF regulation.
    Birk DM; Barbato J; Mureebe L; Chaer RA
    Vasc Endovascular Surg; 2008 Dec-2009 Jan; 42(6):517-30. PubMed ID: 18799497
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Angiopoietin inhibitors: A review on targeting tumor angiogenesis.
    Parmar D; Apte M
    Eur J Pharmacol; 2021 May; 899():174021. PubMed ID: 33741382
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Roles of VEGF-A signalling in development, regeneration, and tumours.
    Matsumoto K; Ema M
    J Biochem; 2014 Jul; 156(1):1-10. PubMed ID: 24839295
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF.
    Ghalehbandi S; Yuzugulen J; Pranjol MZI; Pourgholami MH
    Eur J Pharmacol; 2023 Jun; 949():175586. PubMed ID: 36906141
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibitors of vascular endothelial growth factor in cancer.
    Pourgholami MH; Morris DL
    Cardiovasc Hematol Agents Med Chem; 2008 Oct; 6(4):343-7. PubMed ID: 18855647
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Response to anti-angiogenesis: an ever changing feature.
    Bertolini F
    Breast; 2011 Oct; 20 Suppl 3():S61-2. PubMed ID: 22015295
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity].
    Izzedine H
    Bull Cancer; 2007 Nov; 94(11):981-6. PubMed ID: 18055316
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-VEGF therapies in the clinic.
    Meadows KL; Hurwitz HI
    Cold Spring Harb Perspect Med; 2012 Oct; 2(10):. PubMed ID: 23028128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.